|Bid||3.62 x 200|
|Ask||4.75 x 100|
|Day's Range||4.22 - 4.35|
|52 Week Range||3.34 - 7.15|
|PE Ratio (TTM)||-3.96|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||10.89|
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Synergy Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to SGYP-US. Comparing the performance and risk of Synergy Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Oppenheimer analyst Derek Archila sees some short-term capital rocky waters for Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and awaits more details post-Trulance launch, but continues to root for the biotech firm's lead chronic idiopathic constipation drug's prospects, reiterating an Outperform rating on the stock with a $9 price target, which represents a just under 102% increase from where the stock is currently trading. Archila explains, "We do think it is imperative the company begin to hold earnings calls now that it has launched Trulance as investors will seek to get more color from management on how the launch is progressing and the managed care landscape. With Symphony notably carrying a roughly 90% prescription capture rate and taking under account gross-to-net discounts around 40%, Archila takes his prior forecast in the ballpark of $3 million to $2.6 million.
Second quarter earnings for the year are due sometime around mid-August from Synergy Pharmaceuticals Inc (NASDAQ:SGYP). When looking at the drug's usage in new CIC patients compared against those switching to over to Trulance, results are revealing a "meaningful percentage" that indicate a stronger, more encouraging uptake down the line considering initial expectations. As such, ahead of the print, the analyst reiterates a Buy rating on shares of SGYP with a $13 price target, which represents a 190% increase from where the stock is currently trading.